Get the Stockscreener App
5.99
0.66%
-0.04
After Hours:
6.01
0.02
+0.33%
Cullinan Therapeutics Inc stock is traded at $5.99, with a volume of 504.45K.
It is down -0.66% in the last 24 hours and down -21.60% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$6.03
Open:
$5.99
24h Volume:
504.45K
Relative Volume:
1.15
Market Cap:
$353.86M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-1.6233
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
-5.52%
1M Performance:
-21.60%
6M Performance:
-27.83%
1Y Performance:
-63.34%
1-Day Range:
$5.92
$6.10
1-Week Range:
$5.92
$6.63
52-Week Range:
$5.89
$17.98
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
5.99 | 356.22M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Resumed | H.C. Wainwright | Buy |
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Cullinan Therapeutics, Inc. $CGEM Shares Bought by Rhumbline Advisers - Defense World
Using R and stats models for Cullinan Therapeutics Inc. forecastingLong Setup & Entry Point Confirmation Signals - newser.com
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? - sharewise.com
How to use a screener to detect Cullinan Therapeutics Inc. breakoutsEarnings Risk Summary & Real-Time Price Movement Reports - newser.com
Cullinan Therapeutics (NASDAQ:CGEM) Raised to Hold at Zacks Research - MarketBeat
Published on: 2025-09-22 14:30:54 - newser.com
Cullinan Therapeutics Hits New 52-Week Low at $6.32 - Markets Mojo
Reversal indicators forming on Cullinan Therapeutics Inc. stockTreasury Yields & Technical Analysis for Trade Confirmation - newser.com
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $26.00 Consensus Price Target from Analysts - MarketBeat
Cullinan Therapeutics Hits New 52-Week Low at $5.89 - Markets Mojo
Cullinan Therapeutics Hits New 52-Week Low at $6.24 Amidst Major Decline - Markets Mojo
using r and stats models for cullinan therapeutics inc. forecastingTrade Volume Report & Weekly Market Pulse Updates - newser.com
Best data tools to analyze Cullinan Therapeutics Inc. stock2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - newser.com
Can Cullinan Therapeutics Inc withstand a market correctionJuly 2025 News Drivers & Long-Term Growth Plans - خودرو بانک
Can technical indicators confirm Cullinan Therapeutics Inc.’s reversalInsider Selling & Daily Chart Pattern Signal Reports - newser.com
Breakouts Watch: Can Cullinan Therapeutics Inc outperform under higher oil prices2025 Historical Comparison & Weekly High Return Stock Forecasts - خودرو بانک
Downgrade Watch: What is the Moat Score of Cullinan Therapeutics Inc2025 Major Catalysts & Technical Pattern Recognition Alerts - khodrobank.com
New Highs: Is Cullinan Therapeutics Inc benefiting from innovation trends2025 Performance Recap & Smart Investment Allocation Tips - خودرو بانک
Published on: 2025-09-20 04:22:55 - خودرو بانک
Is Cullinan Therapeutics Inc. still worth holding after the dipPortfolio Performance Summary & Community Trade Idea Sharing - newser.com
Pullback Watch: Will Cullinan Therapeutics Inc. benefit from government policy2025 Market Sentiment & Stock Timing and Entry Methods - خودرو بانک
Analyzing recovery setups for Cullinan Therapeutics Inc. investors2025 Technical Overview & Real-Time Market Sentiment Alerts - newser.com
Market Pulse: Is DBVT subject to activist investor interest2025 Macro Impact & AI Driven Price Forecasts - khodrobank.com
Aug Chart Watch: Whats the RSI of Cullinan Therapeutics Inc stockQuarterly Growth Report & Fast Moving Stock Watchlists - خودرو بانک
Multi asset correlation models including Cullinan Therapeutics Inc.2025 Earnings Impact & Reliable Trade Execution Plans - newser.com
Performance Recap: What is Cullinan Therapeutics Incs valuation compared to sectorMarket Performance Recap & High Return Stock Watch Alerts - khodrobank.com
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded at Zacks Research - Defense World
Sentiment Recap: Does Cullinan Therapeutics Inc have strong EBITDA margins2025 Technical Overview & Weekly High Conviction Trade Ideas - خودرو بانک
Aug Update: Will Cullinan Therapeutics Inc benefit from seasonalityMarket Growth Review & Reliable Entry Point Trade Alerts - خودرو بانک
Has Cullinan Therapeutics Inc. formed a bullish divergencePortfolio Performance Summary & Community Trade Idea Sharing - newser.com
HC Wainwright Reiterates Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
Will Cullinan Therapeutics Inc. outperform the marketMarket Trend Report & Fast Moving Stock Trade Plans - newser.com
Cullinan Therapeutics, Inc. $CGEM Shares Sold by Goldman Sachs Group Inc. - Defense World
How to monitor Cullinan Therapeutics Inc. with trend dashboardsTrade Ideas & Daily Price Action Insights - newser.com
Cullinan Therapeutics (NASDAQ:CGEM) Given Buy Rating at BTIG Research - MarketBeat
How moving averages guide Cullinan Therapeutics Inc. tradingJobs Report & Momentum Based Trading Signals - newser.com
Retail Surge: What drives Cullinan Therapeutics Incs stock priceJuly 2025 Sector Moves & Intraday High Probability Setup Alerts - khodrobank.com
Portfolio Recap: What is the Moat Score of Cullinan Therapeutics IncWeekly Profit Analysis & Verified Technical Signals - خودرو بانک
Rate Cut: Is Cullinan Therapeutics Inc benefiting from innovation trendsEarnings Growth Summary & Real-Time Market Sentiment Alerts - khodrobank.com
Quarterly Risk: What is the long term forecast for Cullinan Therapeutics Inc stockPortfolio Update Summary & Community Trade Idea Sharing - خودرو بانک
Insider Buy: Can Cullinan Therapeutics Inc outperform under higher oil pricesPortfolio Performance Report & Low Risk Entry Point Tips - khodrobank.com
Support Test: What is the Moat Score of Artisan Partners Asset Management IncJuly 2025 Snapshot & Real-Time Chart Breakout Alerts - خودرو بانک
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer - Nasdaq
Can Cullinan Therapeutics Inc. withstand a market correctionSwing Trade & Stepwise Entry and Exit Trade Signals - خودرو بانک
HC Wainwright Reaffirms Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):